Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.24.1.1.u2
Significant Transactions (Narrative) (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 19, 2022
USD ($)
shares
Sep. 16, 2022
USD ($)
Nov. 01, 2021
USD ($)
lease
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
item
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 26, 2024
$ / shares
Jun. 30, 2023
USD ($)
Warrants, exercise price per share | $ / shares                   $ 0.0001  
General and administrative expenses         $ 2,722,000 $ 3,525,000 $ 9,230,000 $ 16,407,000      
Value of common stock issued         9,000   $ 9,000       $ 1,000
Accrued expenses - noncurrent                     527,000
Purchase price allocated       $ 7,500,000              
Secured Term Loan                      
Secured term loan     $ 22,375,000               13,057,000
Interest rate (as percent)     3.25%                
Cost incurred to attain debt                     $ 120,000
RubrYc Therapeutics Inc [Member]                      
Estimated fair value   $ 650,000                  
Milestone payments $ 5,000,000                    
Amount advanced   484,000                  
Transaction costs   208,000                  
Finance leases   $ 814,000 $ 814,000                
Impairment of current prepaid expense                 $ 288,000    
Impairment of noncurrent prepaid expense                 864,000    
Number of shares issued | shares 5,117                    
Value of common stock issued $ 1,000,000                    
Number of equipment leases | lease     3                
Purchase price allocated $ 1,342,000                    
College Station Investors LLC And Bryan Capital [Member]                      
Total purchase price     $ 28,750,000                
Cash payment     28,000,000                
Fair market value of property     $ 151,450                
Percentage of base rent     6.50%                
Cash consideration for equity interest acquired     $ 50,000                
Number of warrants issued | shares     2,579                
Warrants, exercise price per share | $ / shares     $ 665                
Shares issued under the Warrant | shares     579                
Fair value of the warrant     $ 217,255                
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan                      
Secured term loan     $ 22,375,000                
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock                      
Warrants issuable | shares     1                
Percentage of equity interest     0.01%                
Separation Agreement and General Release [Member]                      
General and administrative expenses           $ 2,130,000          
Period of bi-monthly installments of current base salary             24 months        
Period of bi-monthly installments of target bonus             24 months        
Maximum period for coverage of health insurance             18 months        
COBRA subsidy period             18 months        
Number of times on which lump sum cash payment tis o be made | item             6        
Accrued expenses         $ 1,000,000.0   $ 1,000,000.0        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]                      
Collaboration and license agreement, agreement term       5 years              
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics Inc [Member]                      
Collaboration and license agreement, royalty payment term       10 years              
Series A-2 Preferred Stock [Member]                      
Purchase price allocated                 $ 1,760,000    
Series A-2 Preferred Stock [Member] | Series A-2 Preferred Stock [Member]                      
Purchase price allocated       $ 1,760,000              
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]                      
Stock purchase agreement, number of shares purchased | shares       2,864,345              
Stock purchase agreement, value of shares purchased       $ 7,500,000